Patents by Inventor Neil Brewis

Neil Brewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti P2X7 receptor antibodies and fragments thereof
    Patent number: 12129295
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: October 29, 2024
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20220315652
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: March 10, 2021
    Publication date: October 6, 2022
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTI-MESOTHELIN ANTIBODIES
    Publication number: 20220267421
    Abstract: The present application relates to antibody molecules that bind mesothelin (MSLN). The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer.
    Type: Application
    Filed: July 12, 2019
    Publication date: August 25, 2022
    Applicant: F-star Beta Limited
    Inventors: Jose Munoz-Olaya, Remi Fertin, Francisca Wollerton, Mihriban Tuna, Neil Brewis
  • MESOTHELIN AND CD137 BINDING MOLECULES
    Publication number: 20210309753
    Abstract: The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 7, 2021
    Applicant: F-star Delta Limited
    Inventors: Jose Munoz-Olaya, Mihriban Tuna, Remi Fertin, Claire Reader, Francisca Wollerton, Neil Brewis
  • Anti P2Xreceptor antibodies and fragments thereof
    Patent number: 10988532
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 27, 2021
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20190040129
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: July 11, 2018
    Publication date: February 7, 2019
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Anti P2X7 receptor antibodies and fragments thereof
    Patent number: 10053508
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 21, 2018
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20170327576
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: May 18, 2017
    Publication date: November 16, 2017
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Anti P2Xreceptor antibodies and fragments thereof
    Patent number: 9688771
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 27, 2017
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20150266969
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: March 27, 2015
    Publication date: September 24, 2015
    Applicant: BIOSCEPTRE INTERNATIONAL LIMITED
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Anti P2X7 receptor antibodies and fragments thereof
    Patent number: 9127059
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: September 8, 2015
    Assignee: Biosceptre International Limited
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Ligand
    Publication number: 20100081792
    Abstract: The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.
    Type: Application
    Filed: October 31, 2007
    Publication date: April 1, 2010
    Applicant: SmithKline Beecham Corporation
    Inventors: Steven Grant, Amrik Basran, Olga Ignatovich, Rudolph Maria T. De Wildt, Philip Jones, Neil Brewis, Ben Woolven, Elena De Angelis, Lucy J. Holt, Greg Winter, Ian Tomlinson, Kevin Moulder
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS
    Publication number: 20090258012
    Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
    Type: Application
    Filed: March 24, 2009
    Publication date: October 15, 2009
    Applicant: Domantis Limited
    Inventors: Olga Ignatovich, Rudolf Maria Theodora de Wildt, Benjamin Woolven, Steven Grant, Philip C. Jones, Amrik Basran, Neil Brewis
  • Single domain antibodies against tnfr1 and methods of use therefor
    Publication number: 20080008713
    Abstract: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.
    Type: Application
    Filed: October 7, 2005
    Publication date: January 10, 2008
    Applicant: Domantis Limited
    Inventor: Neil Brewis
  • Compositions comprising a fragment of the herpesviral protein vp22 for delivery of substances to cells
    Publication number: 20070105765
    Abstract: This invention relates to aggregated compositions comprising short peptides, or sub-sequences, of full length VP22 protein for delivery of substances such as nucleic acids and proteins into cells. The invention relates to such compositions in themselves, and to methods for their manufacture and use.
    Type: Application
    Filed: September 9, 2004
    Publication date: May 10, 2007
    Inventors: Peter O'Hare, Kavitha Sunassee, Neil Brewis
  • Delivery of substances to cells
    Publication number: 20060189558
    Abstract: Aggregates comprising VP22 protein and oligonucleotides or polynucleotides can be used together with a disaggregating agent (simultaneously or sequentially) to treat target cells by delivery of molecules to the cells and/or to prevent cell proliferation and/or to kill cells.
    Type: Application
    Filed: September 9, 2005
    Publication date: August 24, 2006
    Inventors: Peter Francis O'Hare, Neil Brewis, Nadia Normand, Kavitha Sunassee
  • Fc fusion
    Publication number: 20060083747
    Abstract: The present invention relates to a simple method for generating antibody-based structures suitable for in vivo use. In particular, the invention relates to a method for the generation of antibody-based structures suitable for in vivo use comprising the steps of: (a) selecting an antibody single variable domain having an epitope binding specificity; and (b) attaching the single domain of step (a) to an effector group. Uses of molecules generated using the method of the Invention are also described.
    Type: Application
    Filed: June 24, 2005
    Publication date: April 20, 2006
    Inventors: Gregory Winter, Ian Tomlinson, Olga Ignatovich, Neil Brewis
  • Compositions and methods for treating inflammatory disorders
    Publication number: 20060073141
    Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
    Type: Application
    Filed: April 4, 2005
    Publication date: April 6, 2006
    Inventors: Olga Ignatovich, Rudolf de Wildt, Benjamin Woolven, Steven Grant, Philip Jones, Amrik Basran, Neil Brewis
  • Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
    Publication number: 20060002935
    Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
    Type: Application
    Filed: November 10, 2004
    Publication date: January 5, 2006
    Applicant: Domantis Limited
    Inventors: Neil Brewis, Benjamin Woolven, Steve Holmes, Ian Tomlinson
  • Compositions and methods for treating inflammatory disorders
    Publication number: 20050271663
    Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
    Type: Application
    Filed: August 24, 2004
    Publication date: December 8, 2005
    Inventors: Olga Ignatovich, Rudolf de Wildt, Benjamin Woolven, Steven Grant, Philip Jones, Amrik Basran, Neil Brewis